Assess whether pediatric studies are necessary or waivable (df43f5)

Situation

Biosimilar analytical similarity report arrived with a CRL citing manufacturing, not efficacy for pediatric-plan strategist. That is a Pharma & Life Sciences CMC and Development Pathways decision on pediatric studies are necessary in a company with a CMC site change mid-review.

Decision

Pediatric-plan strategist in a company with a CMC site change mid-review must choose Pediatric studies are necessary / Waivable using biosimilar analytical similarity report after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• Authorize Pediatric studies are necessary now; biosimilar analytical similarity report already has the discriminator after a CRL citing manufacturing, not efficacy.
• Keep Waivable in force until biosimilar analytical similarity report is completed after a CRL citing manufacturing, not efficacy for pediatric-plan strategist.
• Treat biosimilar analytical similarity report as Pediatric studies are necessary because both readings appear after a CRL citing manufacturing, not efficacy.
• Refuse a Pharma & Life Sciences close: pediatric-plan strategist does not have the page pediatric studies are necessary turns on in biosimilar analytical similarity report.

Analysis required

• Check whether biosimilar analytical similarity report supports the labeled claim pediatric-plan strategist would keep.
• Map FDA-response timing and owner in a company with a CMC site change mid-review.
• Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a CRL citing manufacturing, not efficacy.
• For this Pharma & Life Sciences CMC and Development Pathways file, read biosimilar analytical similarity report against a CRL citing manufacturing, not efficacy and write the one fact that would move pediatric studies are necessary for pediatric-plan strategist.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / CMC and Development Pathways packet (biosimilar analytical similarity report after a CRL citing manufacturing, not efficacy). If biosimilar analytical similarity report cannot force a Pharma & Life Sciences label under CMC and Development Pathways, stop. If biosimilar analytical similarity report after a CRL citing manufacturing, not efficacy cannot support Pediatric studies are necessary versus Waivable on this Pharma & Life Sciences CMC and Development Pathways close, pediatric-plan strategist must state the unresolved clinical or safety evidence requirement explicitly.